Cardiometabolic 2026: 5 Heart-Disease Catalysts Ranked

Every retail biotech dollar in 2026 is chasing the same three letters: GLP-1. Novo Nordisk and Lilly own the obesity conversation, and the GLP-1 market roundup is the most-read piece on this site. That crowding is exactly why the real opportunity is elsewhere. The cardiometabolic pipeline outside obesity is delivering multiple approval-stage drugs with $1 billion-plus total addressable markets, and the lipid and RNAi convergence is the pattern to own. Here are five catalysts still ahead, ranked by how much they will actually move a stock.

Catalyst 1: NewAmsterdam obicetrapib, PREVAIL interim Q4 2026

This is the pure binary. NewAmsterdam (NAMS) won CHMP approval in July for obicetrapib, the first CETP inhibitor to clear a major regulator in 20 years of trying. The EU said yes on lipid-lowering alone. The FDA will not. The US path runs through PREVAIL, the 9,541-patient outcomes trial whose primary endpoint is major adverse cardiovascular events. An interim read is expected in the fourth quarter.

The class history is brutal: torcetrapib, dalcetrapib, evacetrapib, and anacetrapib all died in outcomes trials despite lowering LDL. Obicetrapib is mechanistically cleaner, with a two-week half-life and no aldosterone or blood-pressure signal. Its Phase 3 LDL reductions, 33% in BROADWAY and 36.3% in BROOKLYN, are competitive with injectable PCSK9 inhibitors, and BROADWAY showed a 21% reduction in major adverse cardiovascular events at one year, a directional signal that no prior CETP inhibitor ever produced. But that signal was not the primary endpoint and was not powered for significance, so the prior probability of a positive PREVAIL remains low. At $3.47 billion market cap with zero revenue, NAMS is pricing a PREVAIL win, a US approval, and a successful launch as if all three are already decided. The CETP redemption analysis walked the math: a positive PREVAIL re-rates this toward $6 to $8 billion; a miss cuts it to $1 to $1.5 billion. The PREVAIL trial listing confirms the design. Do not buy this ahead of the read. Wait for the interim, then buy the pullback if it hits.

Catalyst 2: Arrowhead plozasiran, ESC data and sNDA by year-end

Arrowhead (ARWR) has the better drug and the worse launch. Plozasiran cut triglycerides 79% to 81% in SHASTA-3 and SHASTA-4 versus roughly 27% for placebo, and it drove a 78% reduction in acute pancreatitis events, reaching 100% in the sickest subgroup. Those numbers beat Ionis’s TRYNGOLZA, which is already approved and generated $32 million in first-half 2026 sales. Arrowhead spent up to $110 million on a priority review voucher to sprint toward an sNDA before year-end, a concession that it is second to market. The plozasiran filing strategy is covered in detail.

Arrowhead’s dosing is quarterly, four injections a year, against Ionis’s monthly autoinjector, and convenience is a real lever in a chronic condition. The August 30 ESC catalyst has now landed: Arrowhead presented the full 12-month SHASTA dataset as a late-breaker at the European Society of Cardiology meeting, confirming a 78% pancreatitis reduction (RR 0.22, p=0.008), 79-81% median triglyceride cuts, a 91% pancreatitis reduction in the highest-risk subgroup, and a clean safety profile. The stock trades around $84-87 with a roughly $12 billion market cap. The trade was never the ESC presentation; it is the first two quarters of commercial data after the year-end sNDA and eventual approval. Every prescription Ionis writes between now and then is one Arrowhead has to switch rather than capture. At $12 billion, the market is pricing the pipeline, not just plozasiran, and the launch is the first real test of whether Arrowhead can commercialize against an entrenched competitor.

Catalyst 3: Alnylam zilebesiran, the ZENITH outcomes trial

Alnylam (ALNY) is the reason the two big 2026 cardiometabolic failures did not hurt the RNAi thesis. Its drug Amvuttra is already the first RNAi approved for ATTR cardiomyopathy, which means Ionis and AstraZeneca’s eplontersen Phase 3 miss cleared a competitor from Alnylam’s lane rather than creating one. The next needle-mover is zilebesiran, the twice-yearly RNAi for hypertension that silences angiotensinogen. The Phase 2 KARDIA program is complete, and Roche has signed on to co-develop the Phase 3 ZENITH trial, an 11,000-patient cardiovascular outcomes study.

Hypertension is a $30 billion global market where half of patients abandon their daily pills within a year. A twice-yearly injection attacks the adherence problem directly. The KARDIA Phase 2 program is done and clean: KARDIA-1 showed a greater-than-15 mmHg placebo-adjusted systolic reduction at three months, and KARDIA-2 added up to 12.1 mmHg on top of standard of care, with no serious drug-related adverse events. The catch is time: ZENITH data lands in 2028 or 2029, so this is not a near-term trade. Alnylam closed at $236.22 with a $30.7 billion market cap, down from $37 billion after a July 30 guidance cut covered in the ALNY earnings piece. The zilebesiran read on hypertension is the long-dated option that justifies owning Alnylam for the platform, not the quarter.

Catalyst 4: Madrigal Rezdiffra, the MASH commercial ramp

Madrigal (MDGL) is the only company here with a real, growing revenue stream. Rezdiffra, the first approved MASH drug, did $364.3 million in Q2 2026 net sales, up 71% year over year, and crossed 50,000 active patients in July. The resmetirom PDUFA coverage tracks the full history. At $516.74 per share and a $12 billion market cap, Madrigal is priced for continued execution, and the next catalyst is not a binary readout but the MAESTRO-NASH-OUTCOMES confirmatory trial that converts the accelerated approval into full approval. The risk is that confirmatory data fails to verify benefit, which would let the FDA withdraw the label. That is a slow burn, not a crash, and it is the difference between a catalyst and a position.

Catalyst 5: Merck LIPFENDRA, the oral PCSK9 launch

Merck (MRK) already won. LIPFENDRA became the first once-daily oral PCSK9 inhibitor on July 16, and Merck priced it at $315 a month, roughly half the injectable PCSK9 cost of $500 to $600 and far below the $14,000-plus annual price that kept Amgen’s Repatha and Regeneron’s Praluent stuck under $1 billion in sales for a decade. The LIPFENDRA approval coverage has the trial data: 56% and 59% placebo-adjusted LDL reduction. The problem is that Merck is a $390 billion company. A best-case LIPFENDRA franchise of a few billion in peak sales is a rounding error against a revenue base anchored by Keytruda. This is an approval, not a stock catalyst. Watch it for what it does to the class, not to Merck’s share price.

The risks

The structural risk across this whole sector is the same one that killed the CETP class and Novo’s ziltivekimab: a drug can lower a biomarker and still do nothing for outcomes. Ziltivekimab hit its molecular target, free IL-6 and hsCRP both dropped, and the ZEUS trial still produced a dead-flat MACE hazard ratio of 0.99. That is the cautionary template for every lipid and inflammation readout still ahead. The second risk is time. The outcomes trials that matter here, ZENITH and the MAESTRO confirmatory, read out years from now, which means capital is locked up waiting on data that can only disappoint once. The third is crowding. Oral lipid-lowering is no longer a wide-open lane now that Merck has an approved pill, and a late entrant without a differentiated outcomes signal is competing on price against generic statins and ezetimibe.

The verdict

The two failures that defined cardiometabolic in 2026, eplontersen and Novo’s ziltivekimab, as covered in the ZEUS Phase 3 miss, did the useful work of clearing the field. What remains is a tighter set of survivors. NewAmsterdam is the highest-octane binary and the only one to avoid into the event. Arrowhead is the better data with a second-mover problem, trade it on the commercial print, not the ESC slide deck. Alnylam and Madrigal are the platform and commercial anchors you hold through the noise. Merck is a footnote. The pattern to own is the lipid and RNAi convergence, and the antisense versus RNAi platform war is where the real multiple expansion will come from over the next two years.